Norverapamil hydrochloride

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

钙通道阻滞剂和维拉帕米的主要活性代谢物。

A calcium channel blocker and the main active metabolite of verapamil.

Norverapamil hydrochloride ((±)-Norverapamil hydrochloride) is similarly effective as verapamil at inhibiting isoniazid and rifampicin tolerance and killing of intracellular M. tuberculosis in the absence of other drugs. norverapamil, also inhibits macrophage-induced tolerance and achieves similar serum levels to verapamil. Verapamil and its major metabolite norverapamil were identified to be both mechanism-based inhibitors and substrates of CYP3A and reported to have non-linear pharmacokinetics in clinic.

Norverapamil hydrochloride (9 mg/kg; p.o.), a major metabolite of verapamil, has terminal half-life, AUC and Cmax values of 9.4 hours, 260 ng?h/ml, and 41.6 ng/mL, respectively. Animal Model:Male Sprague-Dawley rats Dosage:9 mg/kg (Pharmacokinetic Study)Administration:Oral administration Result:t1/2=9.4 hours;AUC=260 ng?h/mL;Cmax=41.6 ng/mL.

±)-Norverapamil hydrochloride | D591 hydrochloride

GPCR/G Protein

Calcium Channel

Calcium Channel

Cancer

——

67812-42-4

477.036

C26H37ClN2O4

>98% (HPLC)

DMSO: ≥ 31 mg/mL

N#CC(C(C)C)(C1=CC=C(OC)C(OC)=C1)CCCNCCC2=CC=C(OC)C(OC)=C2.[H]Cl

Benzeneacetonitrile, α-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-3,4-dimethoxy-α-(1-methylethyl)-, hydrochloride (1:1)

(-20℃)

With Ice Pack

≥ 2 years